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Abstract: Plasminogen activator inhibitor-1 (PAI-1) is a biologically important serine protease inhibitor (serpin) that, when overexpressed, is associated with a high risk for cardiovascular disease and
cancer metastasis. Several of its ligands, including vitronectin, tissue-type and urokinase-type
plasminogen activator (tPA, uPA), affect the fate of PAI-1. Here, we measured changes in the solvent accessibility and dynamics of an important unresolved functional region, the reactive center
loop (RCL), upon binding of these ligands. Binding of the catalytically inactive S195A variant of
tPA to the RCL causes an increase in fluorescence, indicating greater solvent protection, at its
C-terminus, while mobility along the loop remains relatively unchanged. In contrast, a fluorescence
increase and large decrease in mobility at the N-terminal RCL is observed upon binding of S195AuPA to PAI-1. At a site distant from the RCL, binding of vitronectin results in a modest decrease in
fluorescence at its proximal end without restricting overall loop dynamics. These results provide
the new evidence for ligand effects on RCL conformation and dynamics and differences in the
Michaelis complex with plasminogen activators that can be used for the development of more specific inhibitors to PAI-1. This study is also the first to use electron paramagnetic resonance (EPR)
spectroscopy to investigate PAI-1 dynamics.
Significance: Balanced blood homeostasis and controlled cell migration requires coordination
between serine proteases, serpins, and cofactors. These ligands form noncovalent complexes,
which influence the outcome of protease inhibition and associated physiological processes. This
study reveals differences in binding via changes in solvent accessibility and dynamics within these

Abbreviations: DTT, dithiothreitol; EPR, electron paramagnetic resonance; ki, second-order rate of inhibition; klim, limiting rate of
insertion; MTSL, 2,5-dihydro-2,2,5,5-tetramethyl-3-[[(methylsulfonyl)thio]methyl]-1H-pyrrol-1-yloxy; NBD, N,N0 -dimethyl-N-(iodoacetyl)-N0 -(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine; PAI-1, plasminogen activator inhibitor-1; RCL, reactive center loop;
Serpin, serine protease inhibitor; SMB, somatomedin B domain; t1=2, half-life; tPA, tissue plasminogen activator; uPA, urokinase
plasminogen activator; uPAR, urokinase plasminogen activator receptor; d, linewidth; sc, rotational correlation time
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complexes that can be exploited to develop more specific drugs in the treatment of diseases associated with unbalanced serpin activity.
Keywords: plasminogen activator inhibitor-1 (PAI-1); reactive center loop (RCL); tissue plasminogen
activator (tPA); urokinase plasminogen activator (uPA); vitronectin; serpin; fluorescence; electron
paramagnetic resonance (EPR)

Introduction
Plasminogen activator inhibitor-1 (PAI-1) is a multispecific inhibitor of tissue-type and urokinase-type
plasminogen activators (tPA, uPA) with anti-fibrinolytic,
pro- and anti-adhesive, and pro-inflammatory properties.1–5 PAI-1 slows fibrin clot lysis by inhibiting plasminogen activators at rates approaching the diffusion
limit (ki 5 106 to 107 M21 s21).6 Consequently, too much
PAI-1 can lead to thrombotic states in which excessive
fibrin accumulates, potentially blocking blood vessels
and disrupting oxygen supply to tissues, whereas too little PAI-1 can lead to hyperfibrinolytic or mild bleeding
states.7 Thereby, PAI-1 is an important risk factor in the
development of cardiovascular disease.8–11
Plasminogen activation via tPA and uPA plays a
significant role in cancer metastasis by leading to
basement membrane degradation and facilitating
cell invasion into the bloodstream.12–18 PAI-1 may
appropriately be expected to halt this damage, but,
paradoxically, contributes to the severity of metastasis, presumably by competing with cell surface
receptors (e.g. integrins, uPA receptor) for its cofactor vitronectin.19–22 Thus, PAI-1 is increasingly
being used as a poor prognostic biomarker in these

situations. Also, as its cofactor, vitronectin stabilizes
PAI-1 in its active state to prolong its diverse
functions.23
Since it is an important risk factor in cardiovascular disease and biomarker for several cancers,
PAI-1 is an attractive target in the prevention or
treatment of these diseases. Yet, despite its extensive study, no PAI-1 inhibitor has been approved for
clinical trials, underscoring the importance of further studies into its biology and interactions.24 In
this study, we examine the effects of ligand binding
to PAI-1 on its reactive center loop (RCL), which is
functionally important for protease inhibition and
its self-inactivation. The RCL contains the pseudosubstrate for target serine proteases, and its insertion into the central b-sheet of PAI-1 is the defining
feature in the unusual mechanism for protease inactivation, which involves a dramatic rearrangement
of structure and translocation of the target protease,
bound via a covalent acyl bond, from one pole of
the serpin to the other. Furthermore, the orientation
of the RCL is critical, as its exposure or burial
determines whether PAI-1 is active or inactive
(latent). However, the extensive structural biology

Figure 1. PAI-1 complexes with tPA, uPA, and vitronectin. The serine protease domain of A) S195A-tPA (transparent surface,
gray) [PDB: 5BRR25], B) S195A-uPA (transparent surface, pink) [PDB: 3PB126]. and C) the SMB domain of vitronectin (transparent surface, auburn) are shown bound to PAI-1 [PDB: 1OC027]. Important functional regions in protease inhibition and latency
transition, including the RCL (red), gate (green), shutter (cyan), and flexible joint regions (orange), are also indicated.
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Table I. Characterization of PAI-1 Variants with Single Cysteine Substitutions in the RCL

wt-PAI-1

RCL
position

Residue

n. a.
P13
P12
P11
P9
P8
P6
P5
P3
P10
P20
P30
P40
P50

n. a.
V334
A335
S336
S338
T339
V341
I342
S344
M347
A348
P349
E350
E351

Inhibitora

Substrateb

Latentb

Substrate:
inhibitord

Substrate
PAI-1cys: wte

Half-life (hr)f

80c
68 614
75 6 9
78 6 46
78 6 7
73 6 18
83 6 29
89 6 11
70 6 24
84 6 19
80 6 18
87 6 28
71 6 15
84 6 8

762
28 6 2
762
18 6 1
17 6 1
17 6 2
12 6 1
761
15 6 3
11 6 1
863
964
961
12 6 4

13 6 1
461
18 6 2
561
6 6 0.4
10 6 0.3
561
4 6 0.2
15 6 10
561
12 6 1
461
20 6 10
461

0.1
0.4
0.1
0.2
0.2
0.2
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.1

n. a.
3.9
1.0
2.4
2.3
2.4
1.7
0.9
2.0
1.5
1.1
1.3
1.2
1.6

1.2 6 0.1
1.1 6 0.1
1.2 6 0.03
1.5 6 0.1
1.7 6 0.1
2.7 6 0.1
2.6 6 0.1
2.3 6 0.1
1.8 6 0.04
1.8 6 0.1
1.3 6 0.1
1.6 6 0.03
1.6 6 0.1
1.7 6 0.1

a
Percentage based on amount required to fully inhibit tPA upon titration with varying concentrations of unlabeled PAI-1
as detected by chromogenic assay.
b
Percentage based on densitometry to quantify reaction products separated by SDS-PAGE with Coomassie Blue staining
on a 1:1 mixture of unlabeled PAI-1 and tPA.
c
Estimated percentage based on densitometry to quantify reaction products separated by SDS-PAGE with Coomassie Blue
staining on a 1:1 mixture of wild-type (wt) PAI-1 and tPA.
d
Ratio comparing the percentage of substrate form quantified by densitometry in SDS-PAGE analysis of a 1:1 PAI-1:tPA
mixture relative to the percentage of active form detected from a chromogenic assay.
e
Ratio comparing the percentage of substrate formed for the single cysteine PAI-1 variant relative to wt-PAI-1 from densitometry in SDS-PAGE analysis of 1:1 PAI-1:tPA reaction mixtures.
f
Determined by incubation of PAI-1 at 378C and measuring inhibition of tPA activity over time by wild-type (wt) PAI-1 or
PAI-1 variants labeled with the NBD probe. These values for half lives of the PAI-1 variants are reported in Qureshi, T.
and Peterson, C. B. In this issue; pages 487-498.

approaches that have been used with PAI-1, including
crystallography, molecular dynamics, and hydrogendeuterium exchange, provide an incomplete view of
the RCL, as it is either unresolved or resides in several different apparent conformations in the structures to date.25–33 This is not surprising, since the
loop is surface exposed and inherently flexible, but
the lack of more detailed information limits structurebased approaches to drug design targeting this
region. Of particular interest would be greater insight
into differences between the PAI-1-tPA and PAI-1uPA Michaelis complexes, which can be exploited to
specifically inhibit either interaction.25,26 Differences
determined for the Michaelis encounter complexes
could also explain interesting differences in the
kinetics of inhibition of the two proteases by PAI-1,
including the faster limiting rate of RCL insertion
(klim) in the presence of uPA than tPA, despite similar
second order rates of inhibition (ki).34–37 Also,
although conformational effects of vitronectin binding to PAI-1 on its RCL have been documented,38,39
the effects on dynamics in this region remain
undetermined.
We thereby probed single positions from P13 to
P50 with the fluorescent NBD and paramagnetic
MTSL probes to obtain information about RCL conformation and dynamics, respectively, upon binding
of plasminogen activators and vitronectin. [RCL residues are designated by their position P and distance
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from the P1-P10 scissile bond, with C-terminal residues indicated by a prime (0 )]. These experiments
are aimed at identifying different modes of binding
to the target proteases and also can reveal the
extent to which RCL orientation and dynamics can
be influenced upon vitronectin binding at a remote
site. Our study is the first to employ spin-labeling
and paramagnetic resonance to investigate structural features and RCL dynamics in PAI-1. Also,
while the structure of its encounter complex between
uPA and has been available for some time [Fig.
1(B)], the structure of PAI-1 in complex with tPA
has only recently been determined [Fig. 1(A)],25 and
our study provides significant contributions as it
compares and contrasts the contact surfaces between
the inhibitor and plasminogen activators using
solution-based methods.

Results
Inactive (S195A) plasminogen activators
differentially affect the proximal and distal
regions of the RCL
We created single cysteines along the length of the
RCL, and conjugated the side-chain sulfhydryls to
NBD or MTSL probes. Since serpins employ a
conformation-based inhibitory mechanism, the halflife of PAI-1 is an important measure of correct folding. As shown in Table I, labeled proteins exhibit
small increases in half-life compared with wild type
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(wt), indicating that the overall fold of PAI-1 is not
significantly affected by cysteine substitution and
labeling. Table I also lists relative amounts of inhibitor, substrate, and latent forms of PAI-1 that exist
for each of the variants generated. The amount of
active inhibitor relative to substrate form varies
somewhat among the PAI-1 variants, consistent with
other mutagenesis studies, although these changes
are modest. We observe similar substrate formation
for our single-cysteine mutant proteins compared
with wild type protein, except for PAI-1 mutated at
the P13 position of the RCL. Although this mutation
increases substrate formation, labeling of the P13
residue does not affect protein stability (unlabeled
t1=2 5 labeled t1=2  1.1 h.).
We then measured changes that occurred in the
RCL upon formation of the noncovalent Michaelis
complex with catalytically inactive (S195A) plasminogen activators. The NBD probe was chosen for its
enhanced, blue-shifted and reduced, red-shifted fluorescence in hydrophobic and hydrophilic environments, respectively. As the plasminogen activators
bind PAI-1 at the RCL [Fig. 1(A,B)], increases in
NBD fluorescence can provide information about the
burial of hydrophobic surfaces due to binding. Our
approach in targeting a broad span of positions
within the RCL also has the potential to reveal
important exosite interactions, which are defined as
interactions outside the serpin P4-P30 residues and
the S4-S30 specificity pockets of the protease active
site.
Equimolar S195A-tPA and S195A-uPA were
added to NBD-labeled PAI-1, and the changes in fluorescence recorded [Fig. 2(A,B)]. The resulting fluorescence changes at the RCL are large (up to 275%)
for plasminogen activators bound to PAI-1. In the
immediate vicinity of the scissile bond, a decrease in
fluorescence is observed at P10 and/or P20 positions
in the presence of both plasminogen activators. A
previous report showed that introduction of NBD at
the P10 position reduced the affinity of tPA for
PAI-1, indicating that introduction of the probe at
the active site interferes with the interaction.40 The
observed fluorescence decrease at the P10 -P20 is
thereby consistent with the expulsion of the probe
from the active site, leading to its greater solvent
exposure. The same study also demonstrated that
the probe at a position outside the active site (i.e.
P9) does not interfere with plasminogen activator
binding. The NBD probe at the P40 and P50 positions
in the serpin exosite exhibits opposite fluorescence
changes upon plasminogen activator binding. At the
P40 position, a 23% increase in the presence of
S195A-tPA and a 25% decrease in fluorescence
upon S195A-uPA binding is observed. Similarly, a
110% increase and 1% decrease in fluorescence is
observed in the presence of S195A-tPA and S195AuPA, respectively, at the P50 position. Notably, the
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Figure 2. Changes in solvent exposure of the RCL due to
binding of PAI-1 ligands. 0.5 mM NBD-PAI-1 was added to A)
0.5 mM S195A-tPA, B) 0.5 mM S195A-uPA, or C) 2 lM vitronectin or SMB at ambient temperature in PBS (137 mM
NaCl, 2.7 mM KCl, 10 mM NaH2PO4, 1.8 mM KH2PO4, pH
7.4). Samples were excited at 480 nm and the emission at
530 nm collected. Results are normalized to NBD-PAI-1 alone
to obtain the percent change in fluorescence [(F 2 F0/F0) 3
100] at the RCL upon ligand binding. All experiments were
performed in triplicate and error bars plotted as standard
deviations.

overall change in fluorescence is greater at the Cand N-terminal RCL for S195A-tPA and S195A-uPA,
respectively, with the greatest difference between
the two occurring at P50 (110% increase) for

Ligand Effects on the RCL of PAI-1

Figure 3. EPR spectra of MTSL-PAI-1 in presence of ligands. 2 mM MTSL-PAI-1 was added to equimolar S195A-tPA or 8 mM
S195A-uPA, vitronectin, or SMB in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, 1.8 mM KH2PO4, pH 7.4) at ambient
temperature. EPR spectra from 3310-3410 gauss were collected at a constant frequency of 9.45 GHz. The resulting spectra
for representative RCL positions at A) P9 and B) P10 are shown. The center-field peak is indicated by an arrow.

S195A-tPA and positions P9-P6 (211–275% increase) for S195A-uPA. Binding of the two proteases
to form the encounter complexes clearly occurs
through different interaction surfaces in the vicinity
of the scissile bond and via exosite interactions.

RCL dynamics in the michaelis complex are
affected by uPA, but not tPA, binding
As an alternative inhibition strategy to structurebased design, targeting protein dynamics has the
potential to enhance specificity for a desired target.41–43 To obtain information about RCL dynamics,
the MTSL probe was chosen, which carries an
unpaired electron that, when placed in a magnetic
field, resonates by absorption of microwave energy
equal in energy to the difference in its electronic
states.44 The magnetic field is swept at a constant
frequency, from which the first derivative of the
absorption spectra is obtained. The linewidths (d) of
the resulting spectra provide information on nanosecond dynamics, and depend on the rotational
correlation time, sc, which is the time it takes the
spin-label side chain to rotate 1 radian. Sharper and
broader linewidths, corresponding to larger and
smaller inverse linewidths (d21), thereby indicate
greater and restricted motion, respectively.
Inactive S195A-plasminogen activators were
bound to MTSL-labeled PAI-1 and the EPR spectra
collected. Representative spectra for MTSL at the P9
and P10 positions of PAI-1 in the absence and presence of these ligands are shown [Fig. 3(A,B)]. In
most cases, the high-field peak has a sharp shoulder
resulting from an equilibrium between more than
one conformation, most likely active and latent PAI1.45 At the P9 position [Fig. 3(A)], the low- and high-
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field resonance peaks are significantly broadened
and disappear in the presence of S195A-uPA, possibly due to anisotropic interactions, or weak hyperfine interactions of the unpaired electron with the
more distant nitrogen nucleus of the probe. Analysis
of the center-field peak linewidth for MTSL-PAI-1
indicates further changes in the motional dynamics
of the RCL. In Figure 4, the change in the inverse
linewidth of the center peak, or mobility (DMs), is
plotted with respect to RCL position. These results
reveal that binding of S195A-tPA does not significantly affect the mobility, or dynamics, of the RCL.
In contrast, the mobility of the RCL is considerably
restricted, specifically at the N-terminal P11-P5
positions, in the presence of S195A-uPA.

Figure 4. Changes in RCL dynamics due to ligand binding.
The inverse linewidths (d21) of the central peak from the EPR
spectra (c.f. Fig. 3) were obtained, scaled (see Methods), and
normalized with respect to PAI-1 alone to determine changes
in RCL mobility (DMs). All experiments were performed in
triplicate and plotted with standard deviation error bars.

PROTEIN SCIENCE VOL 25:499—510

503

Vitronectin and SMB binding exert similar
effects on the RCL
As its cofactor, vitronectin significantly affects PAI-1
activity in a fashion that can be pinpointed along
the mechanism pathway for protease inhibition.36,37
In particular, vitronectin binding affects the rate of
RCL insertion upon protease inactivation, with distinct differences in this limiting rate comparing tPA
and uPA.36,37 We thereby measured the impact of
vitronectin binding PAI-1 at the flexible joint region
on the solvent accessibility and dynamics of the
RCL. As expected from binding at a distant region
[Fig. 1(C)], vitronectin induces modest albeit notable
changes in fluorescence at the RCL [Fig. 2(C)]. Residues about the scissile bond (P5-P50 ) show less than
10% change in fluorescence due to vitronectin binding. Interacting with vitronectin also leads to a
10% increase in fluorescence at P12-P11 positions,
indicating a more hydrophobic environment for
these residues. Larger changes occur at residues P9P6, which exhibit a 7 to 15% fluorescence decrease,
indicating greater solvent exposure at these positions. The SMB truncation of vitronectin, which
houses the primary binding site for PAI-1, elicits
similar effects to full-length vitronectin, indicating
that these results are largely due to binding at this
high affinity site. Although there are some effects on
“conformation” or solvent exposure, vitronectin and
its SMB domain do not appear to elicit significant
effects on RCL dynamics (Figs. 3 and 4).

Discussion
PAI-1 employs its RCL to bait and inhibit target proteases, or self-inactivate by adopting an RCLinserted latent conformation. The fate of PA1-1 is
influenced by formation of noncovalent complexes
with its ligands. In circulation, PAI-1 encounters
vitronectin, which localizes it to clot sites where it
primarily inhibits tPA to control fibrinolysis. In the
extracellular milieu, PAI-1 can compete with uPAR
and integrins for binding to vitronectin, and/or
encounter and inhibit uPA, which affects pericellular
proteolysis and cell migration. Under equilibrium
conditions in vitro, we uncovered several differences
in the RCL in these encounter complexes with PAI1, which we accomplished by labeling single positions along the loop with NBD and MTSL probes.
Using fluorescence and EPR, we measured
changes in the conformation and dynamics along the
RCL due to complex formation with PAI-1. We found
that stabilization of PAI-1 by binding of vitronectin
involves changes in the RCL that permit partial
insertion of the P12-P11 residues at the hinge, but
disfavor full insertion by increasing the solvent
exposure of residues at the P9-P6 positions [Fig.
2(C)]. These data provide additional evidence that
VN-mediated stabilization of PAI-1 is not solely via
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steric effects on the shutter region in preventing
RCL insertion [Fig. 1(C)].38,39 Also, these results
imply that destabilizing the P9-P6 region of the RCL
is a potential strategy to inactivate PAI-1 when its
high circulating levels are harmful.
In a previous study, we probed effects of vitronectin binding at only two sites (P9 and P10 ) in the
RCL, and observed similar small changes in the solvent exposure.38 We were surprised to observe that
the degree of exposure/burial reported for these particular residues in our previous work differ somewhat compared with our present study [Fig. 2(C)],
likely reflecting specific effects of buffers and/or pH.
Indeed, recent work from our laboratory using
hydrogen-deuterium exchange methods has demonstrated that buffers have markedly different effects
on protein flexibility at specific loci within PAI-1
(manuscript in preparation). Although there are
subtle differences in the specific results, the overall
conclusion remains the same: vitronectin affects the
conformation of the RCL and increases its solvent
accessibility. Also, while conformational effects are
observed, interaction with vitronectin does not
restrict the overall dynamics of the RCL (Fig. 4),
maintaining RCL flexibility that is key to its interaction and inactivation of multiple protease targets.
With respect to plasminogen activators, several
lines of evidence have suggested similar Michaelis
complexes between the two with PAI-1. For instance,
the difference in ki comparing tPA and uPA inhibition by PAI-1 is small compared with that of the serine proteases, thrombin and plasmin.46 Also, both
plasminogen activators share considerable structural
similarity (RMSD 1.9 Å) and characteristic features of their serine protease domains, including a
catalytic triad, several activation loops, and many
variable loops (37-, 60-, 97-, and 186-loops).47 The
differences that do exist between the two are mainly
in the variable loops, with tPA containing a longer
and more positive 37-loop, a 97-loop that protrudes
less from the domain scaffold, and a much shorter
186-loop than that of uPA. While the crystal structure of the PAI-1-uPA Michaelis complex shows
involvement of the variable loops in exosite interactions with PAI-1, some notable differences have been
revealed with the recent solution of the PAI-1-tPA
Michaelis complex by x-ray crystallography.25 The
contacts between the protease and inhibitor encompass more inaccessible surface area in the PAI-1-tPA
structure than the PAI-1-uPA structure, with residues from the 60-loop, the147-loop, and the 169-loop
all contributing to extensive exosite interactions
with PAI-1.25 In addition to the details that have
emerged recently from the crystallographic work,
several experimental approaches support an important role for the exosite involving interactions of the
37-loop and the P40 -P50 residues of PAI-1.26,35,36,48,49
Such exosite interactions increase serpin-protease

Ligand Effects on the RCL of PAI-1

specificity and binding affinities, but must be
released upon scissile bond cleavage for fast RCL
insertion.50
Our fluorescence and EPR data reveal additional noteworthy differences in the Michaelis complexes of PAI-1 with its target proteases [Figs.
2(A,B) and Fig. 4]. We found that S195A-tPA interacts strongly at the C-terminal P50 position [Fig.
2(A)], likely due to the aforementioned exosite interaction with the 37-loop, while RCL nanosecond
dynamics in this complex are retained (Fig. 4). Also,
the large difference in fluorescence changes at the
P40 -P50 positions in the presence of inactive plasminogen activators is consistent with this exosite interaction being more important for tPA than uPA [Fig.
2(A,B)]35 and with the more extensive interface at
the 37-loop of tPA compared with uPA.25 In sharp
contrast, S195A-uPA interacts strongly with the Nterminal RCL [Fig. 2(B)], which significantly
restricts mobility at this end of the loop (Fig. 4).
Specifically, the significant increase in fluorescence
at the P9-P6 positions in the Michaelis complex with
uPA reveals a new, previously undefined exosite. For
the first time, we report evidence from solutionbased experiments that plasminogen activators rest
differently on the serpin “top,” employing distinct
exosite interactions and mobility constraints on the
RCL in the Michaelis complex. These results are
timely and complement the crystallography results
that outline different positions of the RCL in the
two Michaelis complexes. Likewise, the different
dynamics observed from EPR measurements in the
two complexes are consistent with differences in
loop conformations comparing the uPA-PAI-1 structure26 with the tPA-PAI-1 structure.25 Furthermore,
our results provide a simple explanation for the difference in klim for PAI-1 with plasminogen activators
(klim is a complex kinetic term that mathematically
describes the various factors that affect RCL insertion, including rates of reversible acylation and displacement of the P0 -side of the RCL from the
protease exosite).36,37 Upon uPA docking in the
Michaelis complex, the N-terminal RCL becomes
immobilized. We hypothesize this restriction mediates direct RCL incorporation into the central bsheet, resulting in its faster insertion in the presence of uPA compared with tPA.
The analysis of the crystal structure of the PAI1-uPA Michaelis complex suggests that the P15-P6
RCL residues are mobile based on their average
temperature (B) factor,26 and the inferred high flexibility of the N-terminal RCL in the crystal has been
used to explain its rapid insertion after cleavage.
These observations are seemingly in contrast to our
EPR results and hypothesis for uPA-directed fast
RCL insertion. However, there are important differences between these experiments, including the
obvious challenge of comparing solution-based
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experiments with observations in the crystal. For
instance, the RCL of stable PAI-1 in the absence of
ligands adopts an extended conformation in its crystal structures, while solution evidence indicates
close tethering of the loop to the body of the serpin.31,51 Perhaps more significant is the need to consider the timescale and theoretical basis for EPR
results, which provide information on nanosecond
dynamics related to rotational correlation times, versus the crystallographic B-factor, which is derived
from the distribution of electron density that is
spread out and indicates vibrational motion. Finally,
the particular form of PAI-1 used for crystallography
(i.e. 14-1B PAI-1) contains four mutations in the
core of the protein, while the proteins used for EPR
contain only a single mutation at the site where the
EPR probe is attached. Indeed, the quadruple mutations cause the klim in the presence of both plasminogen activators to be much slower for 14-1B than
native PAI-1, and exhibit opposite results in the
presence of vitronectin.36,37 These key factors likely
account for the reported differences.
Interestingly, residues at the P8-P4 positions
form a kink in the RCL of the crystal structure for
the 14-1B-tPA Michael complex (26), but not in the
14-1B-uPA structure.26 In terms of NBD fluorescence, kink formation is predicted to push RCL
residue side-chains towards the hydrophilic solvent,
resulting in a decrease in fluorescence, as is observed at proximal RCL positions in the presence of
vitronectin, but not plasminogen activators (Fig. 2).
This and other evidence suggests an interesting
hypothesis—the formation of a kink in the proximal
RCL may slow its insertion (i.e. decrease klim or
klatency) and vitronectin induces a kink in the RCL of
native, but not 14-1B, PAI-1 in its complex with
plasminogen activators. Although this is clearly
speculative, this idea could account for (1) the slower
klatency of native PAI-1 in the presence of vitronectin,
(2) the slower klim of 14-1B PAI-1 in the presence of
tPA compared with uPA, (3) the slower klim in the
presence of tPA for the stable 14-1B mutant relative
to native PAI-1, and (4) the increase and decrease in
klim for native and 14-1B PAI-1, respectively, for the
reaction of PAI-1 bound to vitronectin with plasminogen activators.2,25,26,37 The increased fluorescence
at the proximal RCL in the presence of both plasminogen activators [Fig. 2(A,B)] may also indicate
that the kink in the RCL in native PAI-1 is relieved
in the encounter complexes, leading to the faster
klim for native PAI-1 compared with the 14-1B
“stable” mutant of PAI-1.
We conclude that interactions of PAI-1 with
plasminogen activators and vitronectin induce
changes in the conformation and dynamics of the
RCL, providing insight that should be beneficial for
the development of more specific drugs that aim to
inhibit PAI-1 and its encounter complexes. Directing
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inhibitors toward a single PAI-1-plasminogen activator interaction without interfering with other serpinprotease interactions is desirable. More specific
inhibitors should lead to increased efficacy and
decreased undesirable side effects of such drugs.
Also, PAI-1 has many important physiological roles,
and thus it is important not to block its beneficial
functions.24 For example, it can be important to differentially target tPA and uPA as thrombolytics. In
acute ischemic stroke, neurotoxicity caused by bloodbrain barrier permeability resulting from the prolonged presence of tPA can be countered by uPA,
which alleviates the effects of oxidative stress.52–56
In this case, the inhibition of tPA, but not uPA, by
PAI-1 is desired, and the PAI-1-uPA, but not PAI-1tPA interaction, should be targeted. The molecular
details of binding and RCL dynamics in the PAI-1uPA Michaelis complex reported here indicate that
targeting the P9-P6 region of the RCL could specifically affect uPA. This strategy may prolong the beneficial effects of uPA as a thrombolytic. Thus, in
light of the complexity of these molecular interactions and diverse physiological roles that has hindered the progression of inhibitors from bench to
bedside, this new information provides a novel avenue for treating diseases associated with the dysregulation of the PAI-1.

formed into Escherichia coli Rosetta 2 DE3 pLysS
cells (Invitrogen) for growth, expression, and largescale cell harvest. Typical conditions for growth
were 30 to 378C with shaking at 250 to 300 rpm in
terrific broth supplemented with 50 lg/mL kanamycin and 34 lg/mL chloramphenicol. At mid- to late
log phase, cells were cooled to 158C, induced with
1 mM IPTG, and grown overnight. Cells were harvested by centrifugation, treated with protease
inhibitor cocktail (#P8465, Sigma Aldrich Corp., St.
Louis, MO), and lysed by sonication. PAI-1 proteins
were purified at 48C in the presence of 1 mM DTT
in three consecutive steps involving cation exchange
on SP-Sepharose FF, IMAC on chelating-Sepharose
FF charged with nickel, and size-exclusion on
Sephacryl S-100 HR resin (GE Healthcare, Piscataway, NJ), and stored at 2808C in phosphate buffer
(0.05M NaH2PO4, 0.3M NaCl, 1 mM EDTA, 1 mM
DTT, pH 6.25). The purified proteins were subjected
to SDS-PAGE followed by Western blotting (rabbit
anti-human PAI-1) and MALDI-TOF-MS (Bruker
Daltonics MicroFlex) to confirm the identity and
purity for each construct. All protein samples were
HPLC-purified (Agilent Technologies 1200 Series)
from a C18 column (Phenomenex Jupiter4u Proteo
90Å) using a linear 5 to 95% acetonitrile gradient
and mixed with sinapic acid (2.5 mg/mL, Fluka)
before analysis by mass spectrometry.

Methods and Materials
Materials
The nonenzymatic S195A variant of uPA was a kind
gift from Mingdong Huang, Fujian Institute of
Research on the Structure of Matter, Chinese Academy of Sciences, Fujian, China. The single-chain
variant of tPA, two-chain tPA, rabbit anti-human
PAI-1 antibody, and mouse anti-human vitronectin
1E934 antibody were purchased from Molecular
Innovations (Novi, MI); IANBD (#D-2004) from
Molecular Probes (Invitrogen); MTSL (#O875000)
from Toronto Research Chemicals; terrific broth,
kanamycin, and chloramphenicol from RPI Corp,
Mount Prospect, IL; SP-Sepharose FF, chelatingSepharose FF, DEAE Sephacel, blue Sepharose CL6B, heparin Sepharose, Sephacryl S-100 HR, and
Sephacryl S-200 HR from GE Healthcare (Piscataway, NJ). All other reagents were of analytical
grade.

PAI-1 RCL mutagenesis and purification
Oligonucleotide primers were designed to contain a
cysteine mutation at the desired RCL position.
Mutations were introduced to the human PAI-1 gene
(previously cloned into the pET24d(1) vector, a gift
from Grant Blouse, Henry Ford Health Sciences
Center Detroit, MI) via PCR using the Quik Change
II XL Site-directed Mutagenesis kit (Stratagene Inc.,
Cedar Creek, TX). Correct mutants were trans-
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Purification of native monomeric vitronectin
and recombinant SMB
Vitronectin was purified from human plasma by as
described previously.57–59 Briefly, 3 L of plasma
was treated with trypsin inhibitor (Sigma-Aldrich),
precipitated with 1M barium chloride at 48C, the
supernatant ammonium sulfate (50% solution) precipitated, resuspended, and separated by anion
exchange on DEAE Sephacel resin, followed by separation by affinity on blue Sepharose CL-6B, heparin
Sepharose, and size-exclusion on Sephacryl S-200
HR resin. Purified vitronectin was confirmed by
Western blotting (1E934 antibody), and its oligomeric state determined via analytical ultracentrifuge
at 50,000 rpm, 258C (Beckman-Coulter Analytical
Ultracentrifuge XL-A). Resulting spectra were analyzed by Sedphat software and the monomeric state
of vitronectin verified. Vitronectin protein was
stored as an ammonium sulfate precipitate (72.7%
at 48C), and resuspended and dialyzed extensively in
PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM
NaH2PO4, 1.8 mM KH2PO4, pH 7.4) before experimentation. Recombinant SMB domain was expressed as a thioredoxin-fusion protein from a
pET32b vector in Rosetta-gami 2 (DE3) pLysS and
purified via IMAC (nickel Sepharose FF), thrombin
cleavage, and gel filtration (S-100) as described previously (61). Concentrations for vitronectin and SMB
were determined using an extinction coefficient, e, of
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1.0 mL mg21 cm21 59 and 4500 M21 cm21,60 respectively, and molecular weight of 62,000 g/mol61 and
5678 g/mol, respectively.62 For SMB, absorbance
measurements were taken at 276 nm rather than
280 nm since the domain does not contain native
tryptophan residues.

Activity of PAI-1 proteins
tPA was titrated with varying amounts of unlabeled
PAI-1, ranging from substoichiometric to excess concentrations, and incubated for 30 min at ambient
temperature. To determine the amount of active protein, excess Spectrozyme tPA (American Diagnostics
Inc., Stamford, CT) was added to the reactions,
which were then analyzed by the absorbance of pnitroaniline at 405 nm (BioTek Synergy4) after 2
min at 378C. The percentage of active protein was
determined from the equivalent required to fully
inhibit tPA. To determine the amount of substrate
and latent protein in preparations, tPA was titrated
with PAI-1 and incubated as before, and the reactions were analyzed by SDS-PAGE under nonreducing conditions. Digital images of the gels created
using the (Bio-Rad ChemDoc XRS), and densitometry of each band in the lane corresponding to 1:1
PAI-1:tPA was performed (Bio-Rad Quantity OneTM).
The results were normalized to percent of total
intensity after background subtraction, and are
based on at least duplicate measurements from
which averages and standard deviations were
calculated.
The half-life of labeled PAI-1 proteins was determined indirectly from tPA activity over time. NBDlabeled PAI-1 proteins were added at a concentration
in which the quantity of active protein was 1:1 with
0.1 lM tPA (#HTPA-TC, Molecular Innovations,
Novi, MI). PAI-1 was incubated at 378C in MOPS
buffer (0.5 mM, 0.1 M a mM onium sulfate, 0.1 mM
EDTA, pH 7.4) and quenched with 0.1 lM tPA at
various time points. Initial rates were measured by
adding excess Spectrozyme tPA to the reactions and
recording the absorbance of p-nitroaniline at 405 nm
for 5 min. The slope obtained from the latter was
plotted against each time point as tPA activity. The
residual PAI-1 activity was calculated as the negative of tPA activity, normalized, and fit to a onephase exponential decay model using GraphPad
Prism Version 5.0b. The corresponding active halflives for PAI-1 proteins was determined. All experiments were performed in triplicate and data were
collected for 10 half-lives.

Labeling of PAI-1 RCL
DTT was removed from the purified proteins via a
PD-10 column (GE Healthcare Life Sciences) and
eluted in phosphate buffer (0.05M NaH2PO4, 0.3M
NaCl, 1 mM EDTA, pH 6.6) at 48C. The fluorescent
and spin probes, IANBD and MTSL, were dissolved
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in DMSO, and added at 10 to 203 molar excess and
at 10% of the total volume. Reactions were incubated (covered) on ice at 48C from 4 h to overnight
to label. After incubation, free probe was removed
by an additional PD-10 step. Labeling was confirmed
by MALDI-MS as described above, and labeled proteins stored at 2808C in phosphate buffer (0.05M
NaH2PO4, 0.3M NaCl, 1 mM EDTA, pH 6.6). The
degree of NBD labeling was determined using the
following equation:
mol NBD ANBD
MW PAI-1
5
3
mol PAI-1 eNBD mg PAI-1 mL-1
where the ANBD is taken at 492 nm, the extinction
coefficient for NBD, eNBD, is 25,000 M21 cm21, and
the MW of recombinant unglycosylated human PAI1 used for the calculation is 43,000 mg/mmol. The
absorbance of NBD at 280 nm was corrected for as
previously described.38,63 Labeling stoichiometries
with NBD were greater than 90% for most constructs, and 60–70% for a few constructs (P13,
P12, P9, P6, P20 ). MTSL-labeling was confirmed
using a Bruker EMX EPR spectrometer.

PAI-1 RCL fluorescence measurements
NBD-labeled PAI-1, vitronectin, and SMB proteins
were dialyzed in 4 L PBS buffer (137 mM NaCl,
2.7 mM KCl, 10 mM NaH2PO4, 1.8 mM KH2PO4,
pH 7.4) at 48C. Following dialysis, 0.5 lM NBD-PAI1 was added to equimolar S195A tPA or S195A uPA,
or 2 lM vitronectin or SMB, and incubated at room
temperature for 30 min. Following incubation, samples were excited at 480 nm in a luminescence spectrometer (Perkin Elmer LS 50B) and the emission
spectra from 500 to 600 nm collected. The intensity
at 530 nm was obtained and normalized to determine the percent change in fluorescence due to binding according to the following equation:
ðF2F0 Þ
3100
F0
where F is the fluorescence intensity at 530 nm, and
F0 5 FPAI, which is the average fluorescence intensity of NBD-PAI-1 alone at 530 nm. All experiments
were preformed in triplicate.

PAI-1 RCL EPR measurements
MTSL-labeled PAI-1 was dialyzed in 4 L PBS buffer
(137 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4,
1.8 mM KH2PO4, pH 7.4) at 48C and diluted to a
final concentration of 2 lM after the addition of
ligands: 2 lM S195A-tPA (due to limited reagent
available), or 8 lM S195A-uPA, vitronectin, or SMB.
Reactions were incubated at 258C for 30 min. Following incubation, samples were added to a 100 mm
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high-precision quartz capillary (Wilmad Glass, inner
diameter 1.012 6 0.013 mm), sealed with Teflon
plugs, and placed in the cavity of a Bruker EMX
EPR Spectrometer. [Small diameter capillaries were
used to prevent signal loss due to the high dielectric
of the buffer.64] The frequency was held constant in
the X-band (9.45 GHz) and center field was set at
3360 G with a sweep width of 100 G. The time constant and conversion time were set to 655.29 ms and
20.48 ms, respectively, with a resolution in X of 2048
for five scans. Spectra were collected at an attenuation of 10 dB. All other parameters were kept at
default. The mobility of the spin-labeled residue was
determined from the linewidth (d), which was calculated as difference in the field at which the peak
and trough of the central resonance line was
observed. Mobilities were scaled (Ms) according to
the following equation:

Ms5

d21 2d21
i
21
d21
m 2di




where d is the width of central resonance line of residue R1, di is the linewidth of most immobilized R1
(i.e. P10 ), and dm is the linewidth of most mobile R1
(i.e. P8).65 The mean of the scaled mobility was
obtained, and results were normalized to PAI-1
alone according to the following equation:
ðMs0 2Ms0 0 Þ
DMs 5
Ms0 0
where DMs is the change in scaled mobility, Ms0 is
the average scaled mobility in the presence of ligand
and Ms0 0 is the average scaled mobility of PAI-1 in
the absence of ligand. All experiments were performed in triplicate.
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